Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126670 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL10126383 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL11957419 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL31005447 | 0.84 | POLB (0.74) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL16938383 | 0.84 | POLB (0.74) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL12694344 | 0.82 | ALDH1A1 (0.50) | EHMT2EHMT1APOBEC3GPOLBMAPT | |
| SCHEMBL20141792 | 0.81 | POLB (0.57) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL12575545 | 0.81 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL30695197 | 0.81 | POLB (0.57) | EHMT2EHMT1APOBEC3GHSD17B10POLB | |
| SCHEMBL11978900 | 0.81 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| WO-2026042013-A1 | MITOCHONDRIAL THERAPY | INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB) (CH) | 2026-02-26 | — | — | WO | disclosed |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4583890-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | Iovance Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025137213-A1 | FUSION PROTEINS COMPRISING ACID ALPHA-GLUCOSIDASE ENZYMES AND METHODS THEREOF | DENALI THERAPEUTICS INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12145960-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4448746-A1 | FUSION PROTEINS COMPRISING ALPHA-L-IDURONIDASE ENZYMES AND METHODS | Denali Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-2193196-A2 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | Portola Pharmaceuticals, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010059861-A1 | COMPOSITIONS AND METHODS TO MODULATE HAIR GROWTH | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010056765-A2 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009042962-A9 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009079566-A2 | NOVEL ADDL RECEPTOR POLYPEPTIDES, POLYNUCLEOTIDES AND HOST CELLS FOR RECOMBINANT PRODUCTION | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009042962-A2 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2004049800-A1 | MAGNETIC MICROBICIDES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-06-17 | — | — | WO | disclosed |
| CN-1230178-A | Polydithiocarbamate-containing macromolecules and use thereof for therapeutic and diagnostic applications | MEDINOX INC (US) | 1999-09-29 | — | — | CN | disclosed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | EHMT2 1488/4885EHMT1 1237/4885APOBEC3G 2830/4885 |
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | EHMT2 2494/4885EHMT1 2450/4885APOBEC3G 226/4885 |
| US-20240400602-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | EHMT2 938/4885EHMT1 923/4885APOBEC3G 236/4885 |
| US-12145960-B2 | Nucleotide analogues | ITPA, POLB, NUDT1 | EHMT2 2878/4885EHMT1 3389/4885APOBEC3G 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.